A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-22

Study Completion Date

2024-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to gather more information on safety and efficacy of Kovaltry for the prevention and treatment of bleeds in Chinese children, adolescents/adults with severe hemophilia A. In addition, pharmacokinetic parameters of Kovaltry will be assessed in a subset of patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

NCT05707351

Hemophilia A

COMPLETED PHASE3

Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

NCT01810666

Hemophilia A

COMPLETED PHASE4

Drug Use Investigation of Kovaltry in Hemophilia A Patients

NCT02941783

Hemophilia A

COMPLETED

Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A

NCT02930317

Hemophilia A

UNKNOWN PHASE3

Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis

NCT02263066

Hemophilia A

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia A

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A: PTPs <12 years of age

Previously treated severe hemophilia A patients (PTPs) \<12 years of age

Group Type EXPERIMENTAL

Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1

Intervention Type BIOLOGICAL

25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months.

The dose decisions are at the discretion of the investigator.

Part A: PTPs ≥12 to 65 years of age

Previously treated severe hemophilia A patients (PTPs) ≥12 to 65 years of age

Group Type EXPERIMENTAL

Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2

Intervention Type BIOLOGICAL

12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months.

\>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months.

The dose decisions are at the discretion of the investigator.

Part B: PUPs/MTPs <6 years of age

Previously untreated/minimally treated severe hemophilia A patients (PUPs/MTPs) \<6 years of age

Group Type EXPERIMENTAL

Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3

Intervention Type BIOLOGICAL

15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week.

The dose decisions are at the discretion of the investigator.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1

25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months.

The dose decisions are at the discretion of the investigator.

Intervention Type BIOLOGICAL

Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2

12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months.

\>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months.

The dose decisions are at the discretion of the investigator.

Intervention Type BIOLOGICAL

Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3

15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week.

The dose decisions are at the discretion of the investigator.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Part A (PTPs):

* Chinese participants with severe hemophilia A (defined as Factor VIII (FVIII): C \< 1% with one- stage clotting assay documented at the time of screening)
* Currently receiving on-demand or any type of prophylaxis treatment regimen with any FVIII product
* For participants \< 12 years of age, ≥ 50 exposure days (ED); for participants ≥ 12 to 65 years of age, ≥ 150 ED with any FVIII product
* No current evidence of inhibitor
* No history of FVIII inhibitor formation
* Signed informed consent

Part B (PUPs/MTPs):

* Participants must be \<6 years of age at the time of their parent or legal representative's signature of informed consent on the participant's behalf
* Chinese participants with severe hemophilia A (defined as Factor VIII (FVIII): C \< 1% with one- stage clotting assay documented at the time of screening)
* PUPs must have no previous exposure to any FVIII product. MTPs must have no more than 1 ED with any purified FVIII concentrate or 3 exposures with FFP or cryoprecipitate.
* MTPs must have no current evidence of inhibitor antibody as measured by the Nijmegen-modified Bethesda assay (\<0.6 BU/mL) in 2 consecutive samples and must have absence of clinical signs or symptoms of decreased response to FVIII administration. Testing for the 2 negative samples must be performed by the central laboratory at least 1 week but not more than 2 weeks apart. Participants may not receive FVIII product within 72 hours prior to the collection of samples for inhibitor testing.
* PUPs and MTPs must observe a 6-month washout period if they have received subcutaneous factor substitution therapy (emicizumab).
* PUPs may be included if they will receive their first FVIII dose with KOVALTRY for treatment of first bleed and agree to start prophylaxis as part of their care. MTPs may be included if they agree to start prophylaxis as part of their care.

Exclusion Criteria

Part A (PTPs):

* Any other bleeding disease that is different from hemophilia A (e.g. von Willebrand disease, hemophilia B)
* Platelet count \< 100 000/mm\^3
* Impaired renal function (serum creatinine \> 2.0 mg/dL) or active liver disease (alanine aminotransferase/aspartate aminotransferase \[ALT/AST\] \> 5x ULN)
* Human immunodeficiency virus (HIV) positive with an absolute CD4 lymphocyte cell count \< 250 cells/μL
* Known hypersensitivity to the active substance, mouse or hamster protein
* Receiving chemotherapy, immune modulatory drugs other than anti-retroviral chemotherapy, or chronic use of oral or intravenous (IV) corticosteroids (\> 14 days) within the last 3 months.
* Requiring any pre-medication to tolerate FVIII infusions (e.g. antihistamines)
* Currently participating in another investigational drug study, or having previously participated in a clinical study involving an investigational drug within 30 days of signing informed consent or participated in completed interventional clinical studies with BAY81-8973 (Kovaltry)
* Planned major surgery, defined as surgery with respiratory assistance and/or general anesthesia

Part B (PUPs/MTPs):

* Any other bleeding disease that is different from hemophilia A (e.g. von Willebrand disease, hemophilia B)
* Platelet count \< 100 000/mm\^3
* Impaired renal function (serum creatinine \>2× upper limit of normal \[ULN\]) or active liver disease (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] \>5× ULN) based on screening laboratory assessments
* MTPs with history of FVIII inhibitor formation
* Known hypersensitivity to the active substance, mouse or hamster protein
* First treatment with KOVALTRY for high risk bleeding situations (e.g., surgery, intracranial bleed) or requiring intensive or prolonged treatment
* Receiving chemotherapy, immune modulatory drugs other than anti-retroviral chemotherapy, or chronic use of oral or intravenous (IV) corticosteroids (\> 14 days) within the last 3 months.
* Requiring any pre-medication to tolerate FVIII infusions (e.g. antihistamines)
* Currently participating in another investigational drug study, or having previously participated in a clinical study involving an investigational drug within 30 days of signing informed consent or participated in completed interventional clinical studies with BAY 81-8973 (Kovaltry)
* Planned major surgery, defined as surgery with respiratory assistance and/or general anesthesia
* Unable to tolerate volume of blood draws required for study participation

Minimum Eligible Age

0 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No